NCT00385840View on ClinicalTrials.gov

Study to Evaluate the Immunogenicity and Safety of a Second Vaccination With the Adjuvanted Influenza Vaccine Candidate

PHASE2CompletedINTERVENTIONAL
Enrollment

678

Participants

Timeline

Start Date

October 20, 2006

Primary Completion Date

February 1, 2007

Study Completion Date

February 5, 2007

Conditions
Influenza
Interventions
BIOLOGICAL

Influenza Vaccine GSK1247446A

Single dose, intramuscular injection

BIOLOGICAL

FluarixTM

Single dose, intramuscular injection

Trial Locations (4)

2301

GSK Investigational Site, Hamar

2408

GSK Investigational Site, Elverum

4010

GSK Investigational Site, Stavanger

5231

GSK Investigational Site, Paradis

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00385840 - Study to Evaluate the Immunogenicity and Safety of a Second Vaccination With the Adjuvanted Influenza Vaccine Candidate | Biotech Hunter | Biotech Hunter